Roche Holding Future Growth
Future criteria checks 2/6
Roche Holding se prevé un crecimiento anual de los beneficios y los ingresos de 9.9% y 3.3% respectivamente. Se prevé que el BPA sea de grow en 9.3% al año. Se prevé que la rentabilidad de los fondos propios sea de 35.6% en 3 años.
Key information
8.3%
Earnings growth rate
8.6%
EPS growth rate
Pharmaceuticals earnings growth | 21.9% |
Revenue growth rate | 3.4% |
Future return on equity | 36.9% |
Analyst coverage | Good |
Last updated | 05 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 65,200 | 15,447 | 16,159 | 20,625 | 10 |
12/31/2025 | 62,985 | 14,553 | 15,248 | 19,401 | 14 |
12/31/2024 | 59,338 | 13,093 | 13,758 | 18,025 | 12 |
12/31/2023 | 60,441 | 11,498 | 11,446 | 16,095 | N/A |
9/30/2023 | 61,486 | 11,263 | 11,759 | 16,313 | N/A |
6/30/2023 | 63,142 | 11,028 | 12,683 | 17,142 | N/A |
3/31/2023 | 64,784 | 11,725 | 13,273 | 17,779 | N/A |
12/31/2022 | 65,814 | 12,421 | 13,251 | 17,803 | N/A |
9/30/2022 | 66,716 | 13,539 | 15,384 | 19,869 | N/A |
6/30/2022 | 67,617 | 14,657 | 17,516 | 21,935 | N/A |
3/31/2022 | 66,734 | 14,294 | 16,972 | 21,456 | N/A |
12/31/2021 | 65,850 | 13,930 | 16,427 | 20,976 | N/A |
9/30/2021 | 63,974 | 13,975 | 15,197 | 20,346 | N/A |
6/30/2021 | 62,098 | 14,019 | 13,967 | 19,716 | N/A |
3/31/2021 | 61,221 | 14,157 | 12,922 | 19,141 | N/A |
12/31/2020 | 60,343 | 14,295 | 11,876 | 18,566 | N/A |
9/30/2020 | 61,361 | 13,626 | 13,799 | 19,949 | N/A |
6/30/2020 | 62,378 | 12,957 | 15,722 | 21,332 | N/A |
3/31/2020 | 63,065 | 13,227 | 16,607 | 21,859 | N/A |
12/31/2019 | 63,751 | 13,497 | 17,491 | 22,385 | N/A |
9/30/2019 | 62,736 | 12,654 | 16,077 | 21,210 | N/A |
6/30/2019 | 61,721 | 11,810 | 14,662 | 20,034 | N/A |
3/31/2019 | 60,609 | 11,155 | 14,860 | 20,007 | N/A |
12/31/2018 | 59,497 | 10,500 | 15,057 | 19,979 | N/A |
9/30/2018 | 58,611 | 10,483 | 14,526 | 19,131 | N/A |
6/30/2018 | 57,725 | 10,465 | 13,995 | 18,283 | N/A |
3/31/2018 | 56,736 | 9,549 | 13,903 | 18,154 | N/A |
12/31/2017 | 55,746 | 8,633 | 13,811 | 18,024 | N/A |
9/30/2017 | 54,961 | 9,154 | N/A | 17,578 | N/A |
6/30/2017 | 54,176 | 9,675 | N/A | 17,132 | N/A |
3/31/2017 | 53,406 | 9,626 | N/A | 16,067 | N/A |
12/31/2016 | 52,636 | 9,576 | N/A | 15,001 | N/A |
9/30/2016 | 52,109 | 9,332 | N/A | 14,678 | N/A |
6/30/2016 | 51,581 | 9,087 | N/A | 14,354 | N/A |
3/31/2016 | 50,992 | 8,975 | N/A | 14,803 | N/A |
12/31/2015 | 50,403 | 8,863 | N/A | 15,251 | N/A |
9/30/2015 | 50,364 | 8,908 | N/A | 15,077 | N/A |
6/30/2015 | 50,324 | 8,953 | N/A | 14,902 | N/A |
3/31/2015 | 50,095 | 9,143 | N/A | 15,416 | N/A |
12/31/2014 | 49,866 | 9,332 | N/A | 15,930 | N/A |
9/30/2014 | 49,300 | 10,044 | N/A | 16,160 | N/A |
6/30/2014 | 48,733 | 10,756 | N/A | 16,389 | N/A |
3/31/2014 | 48,673 | 10,960 | N/A | 16,081 | N/A |
12/31/2013 | 48,612 | 11,164 | N/A | 15,772 | N/A |
9/30/2013 | 48,502 | 11,167 | N/A | 15,467 | N/A |
6/30/2013 | 48,392 | 11,169 | N/A | 15,162 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: RHHB.F(9% al año) es superior a la tasa de ahorro (2.2%).
Beneficios frente mercado: RHHB.FSe prevé que los beneficios de la empresa (11.1% al año) crezcan menos que el mercado US (14.9% al año).
Beneficios de alto crecimiento: RHHB.FSe prevé que los beneficios de la empresa crezcan, pero no significativamente.
Ingresos vs. Mercado: RHHB.F(3.2% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).
Ingresos de alto crecimiento: RHHB.FSe prevé que los ingresos de la empresa (3.2% al año) crezcan más despacio que 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): RHHB.Fse prevé que la Rentabilidad de los fondos propios sea alta dentro de 3 años (35.6%)